161 related articles for article (PubMed ID: 18651865)
1. Prospective study of combined treatment with interferon-alpha and active vitamin D3 for Japanese patients with metastatic renal cell carcinoma.
Obara W; Mizutani Y; Oyama C; Akaza H; Ishii N; Kohri K; Namiki M; Okuyama A; Shima H; Yokoyama M; Shuin T; Miki T; Watanabe Y; Fujioka T
Int J Urol; 2008 Sep; 15(9):794-9. PubMed ID: 18651865
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.
Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM
Urology; 2004 Jun; 63(6):1061-5. PubMed ID: 15183950
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
Gez E; Rubinov R; Gaitini D; Meretyk S; Best LA; Native O; Stein A; Erlich N; Beny A; Zidan J; Haim N; Kuten A
Cancer; 2002 Oct; 95(8):1644-9. PubMed ID: 12365011
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
5. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
[TBL] [Abstract][Full Text] [Related]
6. Combined immunotherapy with low-dose IL-2 plus IFN-alpha for metastatic renal cell carcinoma: survival benefit for selected patients with lung metastasis and serum sodium level.
Akaza H; Tsukamoto T; Fujioka T; Tomita Y; Kitamura T; Ozono S; Miki T; Naito S; Zembutsu H; Nakamura Y
Jpn J Clin Oncol; 2011 Aug; 41(8):1023-30. PubMed ID: 21642665
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2, interferon-alpha and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma: the all Ireland experience.
O'Brien MF; Rea D; Rogers E; Bredin H; Butler M; Grainger R; McDermott TE; Mullins G; O'Brien A; Twomey A; Thornhill J
Eur Urol; 2004 May; 45(5):613-8; discussion 619. PubMed ID: 15082204
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous administration of interferon alpha and gamma in patients with metastatic renal cell carcinoma.
Koga S; Nishikido M; Matsuya F; Kanetake H; Saito Y
Anticancer Res; 1999; 19(6C):5547-50. PubMed ID: 10697614
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous interleukin-2 and interferon-alpha in metastatic renal cell carcinoma: results of a French regional experience in Languedoc.
Culine S; Iborra F; Mottet N; Avancès C; de Graeve B; Volpé P; Vignoud J; Bringer JP; Marroncle M; Le Pellec L; Ayuso D; Jansen E; Faix A; Rebillard X
Am J Clin Oncol; 2006 Apr; 29(2):148-52. PubMed ID: 16601433
[TBL] [Abstract][Full Text] [Related]
11. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.
Rini BI; Weinberg V; Dunlap S; Elchinoff A; Yu N; Bok R; Simko J; Small EJ
Cancer; 2006 Feb; 106(3):566-75. PubMed ID: 16369983
[TBL] [Abstract][Full Text] [Related]
12. Outpatient treatment with subcutaneous interleukin-2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience.
Marx G; Taylor J; Goldstein D
Intern Med J; 2005 Jan; 35(1):34-8. PubMed ID: 15667466
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide therapy for metastatic renal cell carcinoma.
Amato RJ; Hernandez-McClain J; Saxena S; Khan M
Am J Clin Oncol; 2008 Jun; 31(3):244-9. PubMed ID: 18525302
[TBL] [Abstract][Full Text] [Related]
14. Metastatic renal cancer and patient survival as a criterion of treatment response.
Stathopoulos GP; Koutantos J; Rigatos SK; Stathopoulos J; Batzios S; Batziou C
Oncol Rep; 2008 Feb; 19(2):477-81. PubMed ID: 18202797
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma.
Krzyzanowska MK; Tannock IF; Lockwood G; Knox J; Moore M; Bjarnason GA
Cancer Chemother Pharmacol; 2007 Jun; 60(1):135-41. PubMed ID: 17009033
[TBL] [Abstract][Full Text] [Related]
16. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
Schrader AJ; Heidenreich A; Hegele A; Olbert P; Varga Z; Hofmann R
Aktuelle Urol; 2006 Nov; 37(6):429-35; quiz 423-4. PubMed ID: 17099831
[TBL] [Abstract][Full Text] [Related]
17. Treatment of metastatic renal cell carcinoma with a combination of human lymphoblastoid interferon-alpha and cimetidine.
Kotake T; Kinouchi T; Saiki S; Kuroda M; Miki T; Kiyohara H; Usami M
Jpn J Clin Oncol; 1991 Feb; 21(1):46-51. PubMed ID: 2067120
[TBL] [Abstract][Full Text] [Related]
18. Multi-modal treatment of primarily using continuous subcutaneous interferon-alpha injection in combination with surgery and/or radiotherapy.
Maruoka M; Fujimura M; Kawamura K; Suzuki S; Hamano M; Nishikawa Y; Nagayama T
Int J Urol; 2005 May; 12(5):442-8. PubMed ID: 15948742
[TBL] [Abstract][Full Text] [Related]
19. Treatment of advanced renal cell carcinoma with a combination of human lymphoblastoid interferon-alpha and cimetidine.
Kinouchi T; Saiki S; Maeda O; Kuroda M; Usami M; Kotake T
J Urol; 1997 May; 157(5):1604-7. PubMed ID: 9112486
[TBL] [Abstract][Full Text] [Related]
20. [Significance of interferon alpha therapy for advanced renal cell carcinoma. Fukushima Renal Cancer Study Group].
Ogihara M; Aikawa K; Suzuki T; Yanagida T; Kushida N; Yamaguchi O; Shiraiwa Y; Kumakawa K; Koseki K; Ichijo S; Date T; Kurosu S; Takeuchi M; Yokoyama J; Murakami F; Itoh K; Noguchi M
Gan To Kagaku Ryoho; 2000 Sep; 27(10):1533-9. PubMed ID: 11015998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]